Interleukin-10-independent anti-inflammatory actions of glucagon-like peptide 2

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 295, Issue 6, 2008, Pages

  Ivory, Catherine P A ^a   Wallace, Laurie E ^a   McCafferty, Donna Marie ^a   Sigalet, David L ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Crypt cell proliferation; Interleukin 6; Lamina propria; Signal transducer and activator of transcription 3; Suppressor of cytokine signaling 3

Indexed keywords

GAMMA INTERFERON; GLUCAGON LIKE PEPTIDE 2; INTERLEUKIN 10; INTERLEUKIN 1BETA; MYELOPEROXIDASE; SUPPRESSOR OF CYTOKINE SIGNALING; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CELL POPULATION; CELL PROLIFERATION; CELL SELECTION; COLITIS; CONTROLLED STUDY; FLUORESCENCE; HISTOPATHOLOGY; LAMINA PROPRIA; MALE; MOUSE; MUCOSA INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; WEIGHT REDUCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CELL PROLIFERATION; COLITIS; CYTOKINES; DISEASE MODELS, ANIMAL; GLUCAGON-LIKE PEPTIDE 2; INTERLEUKIN-10; MALE; MICE; MICE, KNOCKOUT; MUCOUS MEMBRANE;

EID: 57349152513     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.90494.2008     Document Type: Article

References (38)

1. Abad C, Martinez C, Juarranz MG, Arranz A, Leceta J, Delgado M, Gomariz RP. Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease. Gastroenterology 124: 961-971, 2003.
2. Arthur GL, Schwartz MZ, Kuenzler KA, Birbe R. Glucagonlike Peptide-2 analogue: a possible new approach in the management of inflammatory bowel disease. J Pediatr Surg 39: 448-452, 2004.
3. Bulut K, Meier JJ, Ansorge N, Felderbauer P, Schmitz F, Hoffmann P, Schmidt WE, Gallwitz B. Glucagon-like peptide 2 improves intestinal wound healing through induction of epithelial cell migration in vitro-evidence for a TGF-beta-mediated effect. Regul Pept 121: 137-143, 2004.
4. Chen Z, Laurence A, Kanno Y, Pacher-Zavisin M, Zhu BM, Tato C, Yoshimura A, Hennighausen L, O'Shea JJ. Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells. Proc Natl Acad Sci USA 103: 8137-8142, 2006.
5. Chung YC, Chang YF. Serum interleukin-6 levels reflect the disease status of colorectal cancer. J Surg Oncol 83: 222-226, 2003.
6. Coombes JL, Powrie F. Dendritic cells in intestinal immune regulation. Nat Rev Immunol 8: 435-446, 2008.
7. Croker BA, Krebs DL, Zhang JG, Wormald S, Willson TA, Stanley EG, Robb L, Greenhalgh CJ, Forster I, Clausen BE, Nicola NA, Metcalf D, Hilton DJ, Roberts AW, Alexander WS. SOCS3 negatively regulates IL-6 signaling in vivo. Nat Immunol 4: 540-545, 2003.
8. Dahly EM, Guo Z, Ney DM. IGF-I augments resection-induced mucosal hyperplasia by altering enterocyte kinetics. Am J Physiol Regul Integr Comp Physiol 285: R800-R808, 2003.
9. Delgado M, Gonzalez-Rey E, Ganea D. VIP/PACAP preferentially attract Th2 effectors through differential regulation of chemokine production by dendritic cells. FASEB J 18: 1453-1455, 2004.
10. Denning TL, Wang YC, Patel SR, Williams IR, Pulendran B. Lamina propria macrophages and dendritic cells differentially induce regulatory and interleukin 17-producing T cell responses. Nat Immunol 8: 1086-1094, 2007.
11. Drucker DJ, Ehrlich P, Asa SL, Brubaker PL. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci USA 93: 7911-7916, 1996.
12. Dube PE, Forse CL, Bahrami J, Brubaker PL. The essential role of insulin-like growth factor-1 in the intestinal tropic effects of glucagon-like peptide-2 in mice. Gastroenterology 131: 589-605, 2006.
13. Fabricius D, O'Dorisio MS, Blackwell S, Jahrsdorfer B. Human plasmacytoid dendritic cell function: inhibition of IFN-alpha secretion and modulation of immune phenotype by vasoactive intestinal peptide. J Immunol 177: 5920-5927, 2006.
14. Gonzalez-Rey E, Delgado M. Therapeutic treatment of experimental colitis with regulatory dendritic cells generated with vasoactive intestinal peptide. Gastroenterology 131: 1799-1811, 2006.
15. Guan X, Karpen HE, Stephens J, Bukowski JT, Niu S, Zhang G, Stoll B, Finegold M, Holst JJ, Hadsell DL, Nichols B, Burrin DG. GLP-2 receptor localizes to enteric neurons and endocrine cells expressing vasoactive peptides and mediates increased blood flow. Gastroenterology 130: 150-164, 2006.
16. Judd LM, Bredin K, Kalantzis A, Jenkins BJ, Ernst M, Giraud AS. STAT3 activation regulates growth, inflammation, and vascularization in a mouse model of gastric tumorigenesis. Gastroenterology 131: 1073-1085, 2006.
17. Keku TO, Sandler RS, Simmons JG, Galanko J, Woosley JT, Proffitt M, Omofoye O, McDoom M, Lund PK. Local IGFBP-3 mRNA expression, apoptosis and risk of colorectal adenomas. BMC Cancer 8: 143, 2008.
18. Kuemmerle JF. Endogenous IGF-I protects human intestinal smooth muscle cells from apoptosis by regulation of GSK-3 beta activity. Am J Physiol Gastrointest Liver Physiol 288: G101-G110, 2005.
19. MacDonald TT. Epithelial proliferation in response to gastrointestinal inflammation. Ann NY Acad Sci 664: 202-209, 1992.
20. Martin GR, Beck PL, Sigalet DL. Gut hormones, and short bowel syndrome: the enigmatic role of glucagon-like peptide-2 in the regulation of intstinal adaptation. World J Gastroenterol 12: 4117-4129, 2006.
21. Martin GR, Wallace LE, Sigalet DL. Glucagon like peptide 2 induces intestinal adaptation in parenterally fed rats with short bowel syndrome. Am J Physiol Gastrointest Liver Physiol 286: G964-G972, 2004.
22. Martin GR, Wallace LE, Hartmann B, Holst JJ, Demchyshyn L, Toney K, Sigalet DL. Nutrient stimulated GLP-2 release and crypt cell proliferation in experimental short bowel syndrome. Am J Physiol Gastrointest Liver Physiol 288: G431-G438, 2005.
23. Metwali A, Blum AM, Elliott DE, Weinstock JV. IL-4 inhibits vasoactive intestinal peptide production by macrophages. Am J Physiol Gastrointest Liver Physiol 283: G115-G121, 2002.
24. Miceli P, Morris GP, MacNaughton WK, Vanner S. Alterations in capsaicin-evoked electrolyte transport during the evolution of guinea pig TNBS ileitis. Am J Physiol Gastrointest Liver Physiol 282: G972-G980, 2002.
25. Munkholm P. Review article: the incidence and prevalence of colorectal cancer in inflammatory bowel disease. Aliment Pharmacol Ther 18, Suppl 2: 1-5, 2003.
26. -/-) mice and intestinal inflammation. Am J Physiol Gastrointest Liver Physiol 278: G829-G833, 2000.
27. Rigby RJ, Simmons JG, Greenhalgh CJ, Alexander WS, Lund PK. Suppressor of cytokine signaling 3 (SOCS3) limits damage-induced crypt hyper-proliferation and inflammation-associated tumorigenesis in the colon. Oncogene 26: 4833-4841, 2007.
28. Roberge JN, Brubaker PL. Secretion of proglucagon-derived peptides in response to intestinal luminal nutrients. Endocrinology 128: 3169-3174, 1991.
29. Scheinin T, Butler DM, Salway F, Scallon B, Feldmann M. Validation of the interleukin-10 knockout mouse model of colitis: antitumour necrosis factor-antibodies suppress the progression of colitis. Clin Exp Immunol 133: 38-43, 2003.
30. Schneider MR, Hoeflich A, Fischer JR, Wolf E, Sordat B, Lahm H. Interleukin-6 stimulates clonogenic growth of primary and metastatic human colon carcinoma cells. Cancer Lett 151: 31-38, 2000.
31. Sigalet DL, Wallace LE, Holst JJ, Martin GR, Kaji T, Tanaka H, Sharkey KA. Enteric neural pathways mediate the anti-inflammatory actions of Glucagon-like Peptide 2. Am J Physiol Gastrointest Liver Physiol 293: G211-G221, 2007.
32. Smythies LE, Sellers M, Clements RH, Mosteller-Barnum M, Meng G, Benjamin WH, Orenstein JM, Smith PD. Human intestinal macrophages display profound inflammatory anergy despite avid phagocytic and bacteriocidal activity. J Clin Invest 115: 66-75, 2005.
33. So EY, Park HH, Lee CE. IFN-gamma and IFN-alpha posttranscriptionally down-regulate the IL-4-induced IL-4 receptor gene expression. J Immunol 165: 5472-5479, 2000.
34. Suzuki A, Hanada T, Mitsuyama K, Yoshida T, Kamizono S, Hoshino T, Kubo M, Yamashita A, Okabe M, Takeda K, Akira S, Matsumoto S, Toyonaga A, Sata M, Yoshimura A. CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation. J Exp Med 193: 471-481, 2001.
35. Tanaka K, Ichiyama K, Hashimoto M, Yoshida H, Takimoto T, Takaesu G, Torisu T, Hanada T, Yasukawa H, Fukuyama S, Inoue H, Nakanishi Y, Kobayashi T, Yoshimura A. Loss of suppressor of cytokine signaling 1 in helper T cells leads to defective Th17 differentiation by enhancing antagonistic effects of IFN-gamma on STAT3 and Smads. J Immunol 180: 3746-3756, 2008.
36. Xin X, Hou YT, Li L, Schmiedlin-Ren P, Christman GM, Cheng HL, Bitar KN, Zimmermann EM. IGF-I increases IGFBP-5 and collagen α1(I) mRNAs by the MAPK pathway in rat intestinal smooth muscle cells. Am J Physiol Gastrointest Liver Physiol 286: G777-G783, 2004.
37. Yusta B, Huang L, Munroe D, Wolff G, Fantaske R, Sharma S, Demchyshyn L, Asa SL, Drucker DJ. Enteroendocrine localization of GLP-2 receptor expression in humans and rodents. Gastroenterology 119: 744-755, 2000.
38. Zimmermann EM, Li L, Hou YT, Mohapatra NK, Pucilowska JB. Insulin-like growth factor I and insulin-like growth factor binding protein 5 in Crohn's disease. Am J Physiol Gastrointest Liver Physiol 280: G1022-G1029, 2001.